Clinical trial
Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis
NCT03963375
Study timeline
Study start (actual)2019-10-28Date precision: day
Registry last updated2026-07-28
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Multiple Sclerosisunresolved
Multiple Sclerosis, Relapsing-Remittingunresolved
Interventions
CladribineDRUG · verified · RxNorm: cladribine
Sponsors & collaborators
Gregory Wulead sponsor
EMD Seronocollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03963375 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.